who become exposed to the virus by a marrow graft from a CMV positive donor or by blood products. Several randomized trials of the effectiveness of CMV hyperimmune A randomized multicentre study was conducted to evaluate the effect of anti-CMV hyperimmune globulin globulin or plasma in the prevention of CMV infection and disease in BMT patients have given conflicting results. 4, 6 in the prophylaxis of CMV infections in CMV seronegative allogeneic BMT patients who received a transplant We have carried out a randomized multicentre trial to study the effectiveness of intravenous CMV hyperimmune globufrom a seropositive donor or who had received blood products unscreened for CMV during the treatment lin in the prevention of CMV infection and disease in seronegative bone marrow transplant recipients who before BMT. Twenty-eight patients were included in the study. Thirteen were randomized to receive and 15 not received a transplant from a seropositive donor or had been given blood products unscreened for CMV before BMT. to receive intravenous CMV hyperimmune globulin. A dose of 0.4 g/kg of immunoglobulin was given on day ؊8 and 0.2 g/kg on days ؊1, ؉7, ؉14, ؉21, ؉28, ؉35, ؉42, ؉56 and ؉70 in relation to the day of transplanPatients and methods tation. Among the 15 patients not given immunoglobulin CMV was isolated in three, and two of them developed Patients clinical CMV disease. In addition, one more patient Twenty-eight CMV seronegative patients treated with allodeveloped CMV antibodies without virus isolation. In geneic BMT were included in the study. All the patients five of the 13 patients given immunoglobulin the virus were CMV seronegative as determined by ELISA-based could be isolated, and four of them developed CMV distechniques at each centre 3-4 weeks prior to the transplanease. One additional patient showed seroconversion but tation. They either received a transplant from a CMV serono other findings of CMV infection. The incidence of positive donor (25 patients), or the transplant was from a acute and chronic GVHD was similar in the two arms.
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seronegative donor but blood transfusions unscreened for There was no significant difference in survival. In con-CMV had been given during the treatment before the transclusion, the present results do not indicate a beneficial plantation (three patients). The patients were randomized effect of CMV hyperimmune globulin infusions in the to receive (n ϭ 13) or not to receive (n ϭ 15) CMV hyperprophylaxis of CMV infection or disease in seronegative immune globulin. Patient characteristics are shown in Table  allogeneic bone marrow transplant recipients from a 1. The pretransplant conditioning and GVHD prophylaxis seropositive donor.
were given according to routine practice at each centre. Keywords: cytomegalovirus hyperimmune globulin; More than half of the patients received low-dose acyclovir cytomegalovirus infection; allogeneic bone marrow transfor herpes simplex virus prophylaxis, but no other prophyplantation lactic antiviral agent was permitted. The immunoglobulin treated and control groups were similar, no significant differences were observed. Cytomegalovirus (CMV) infection is very common after allogeneic bone marrow transplantation (BMT) 1,2 and may Immunoglobulin cause serious, even fatal disease. Specific prophylaxis of CMV infection is possible with antiviral drugs and CMV The CMV hyperimmune globulin was produced by the hyperimmune globulin or plasma. [3] [4] [5] set to a level adopted by the Massachusetts Public Health Blood transfusions
The red cell and platelet transfusions given to the patients The characteristics of the study groups were compared using Fisher's exact test. Kaplan-Meier survival curves Biologic Laboratories (Boston, MA, USA), where Dr were analysed with the log-rank test. Jeanne Leszczynski kindly performed the comparative testing of the plasma. Of the Finnish blood donor population, 7% have a titre which is equal to or higher than the cutResults off limit. The plasma was fractionated in the Central Laboratory of the Swiss Red Cross Blood Transfusion Service Thirteen patients were randomized to receive immunoglob-(Basel, Switzerland) using the same method as for the fraculin. The average increase of serum anti-CMV IgG level tionation of Sandoglobulin (Swiss Red Cross Blood Transwas 143 Abbott units (AU) (4.8 PEU)/ml after a 0.4 g/kg fusion Service). In this method the Fc-portion of the dose and 108 AU (3.6 PEU)/ml after a 0.2 g/kg dose. immunoglobulin is not affected. The final product was Ten out of the total 28 patients developed CMV infection tested for the presence of neutralizing anti-CMV antibodies and six had CMV disease. Four patients had CMV isolated in the Statens Bakteriologiska Laboratorium (Stockholm, from blood, four from urine, three from the throat, one from Sweden) and in the Bernard Nocht-Institute (Hamburg, a liver biopsy, and one from broncho-alveolar lavage fluid. Germany). The batch of anti-CMV intravenous immunoThe median time from the transplantation to the first isoglobulin used in this study contained 80 Paul Ehrlich lation was 49 days. units (PEU)/mg.
Among the 13 patients who received immunoglobulin, A 6% solution of the hyperimmune globulin was adminthe virus could be isolated in five ( Table 2) . Four of them istered in the dose of 0.4 g/kg on day Ϫ8, and in the dose developed CMV disease. One had cytopenia and fever, one of 0.2 g/kg on days Ϫ1, ϩ7, ϩ14, ϩ21, ϩ28, ϩ35, ϩ42, interstitial pneumonia, one pneumonia, hepatitis and cyto-ϩ56, and ϩ70 in relation to the day of transplantation. penia, and one hepatitis. In two of the four patients with CMV disease, seroconversion could not be evaluated CMV serology and isolation because of immunoglobulin infusions and early death. Two of the three remaining patients with positive CMV isolation CMV IgG antibody concentrations were determined with ELISA methods in routine use at each centre 3-4 weeks seroconverted. One additional patient had a seroconversion, Among the 15 patients not given immunoglobulin CMV could be isolated in three patients. Two of them developed CMV disease, hepatitis in one and pneumonia and cytoin either CMV infection or CMV disease as a result of penia in the other. One of the patients with CMV disease CMV hyperimmune globulin administration. No effect was showed seroconversion, the other patients with positive seen in the study of Bowden et al. 9 Among seronegative CMV isolation did not seroconvert. Furthermore, one recipients of marrow from a seropositive donor, Bowden et additional patient developed CMV antibodies, but attempts al 10 found a reduction of CMV infections in patients given to isolate the virus were negative, and the patient had no CMV hyperimmune globulin prophylaxis, but there was no clinical symptoms.
difference in the incidence of CMV disease. In other studies Of the four patients given immunoglobulin prophylaxis no positive effect was found in this subgroup of patients. 7, 9 who developed CMV disease, two had received low-dose With the exception of the study by Bowden et al, 10 the acyclovir prophylaxis against herpes simplex virus. Both numbers of seronegative recipients of a graft from a seropatients in the control arm who had CMV disease had been positive donor, when specified, have been small, and the given prophylaxis with low-dose acyclovir. Two of the four present patient material is one of the largest published. patients with CMV infection but no CMV disease had More than half of the patients had received low-dose acyreceived acyclovir.
clovir prophylaxis against herpes simplex virus infections. One of the three patients who had a seronegative donor Whether this drug was given or not was, however, probably but had received unscreened blood products developed not an essential factor in the development of CMV infection CMV infection but no CMV disease. and disease, since four of the six patients with CMV disease There was no difference between the study groups in the had received acyclovir prophylaxis. incidence or severity of GVHD (Table 2 ). There was no
The results of the present study have to be interpreted clear association between the presence of GVHD and CMV with caution. The number of patients is relatively small, disease. Of the six patients with CMV disease, two had no and there is heterogeneity in the study population in regard GVHD, two had acute GVHD grade I and two grade II.
to the diagnosis of the underlying disease as well as the Figure 1 shows the Kaplan-Meier survival curves of the management at different centres. However, CMV infection patients given immunoglobulin and the controls. The surand disease was seen in about 30% of patients given CMV vivals did not differ significantly.
hyperimmune globulin prophylaxis, and it is unlikely that a significant prophylactic effect would have been seen even if the patient groups had been considerably larger, which Discussion was the major reason for stopping this trial.
In conclusion, the present results do not indicate a beneIn this study CMV seronegative allogeneic BMT patients ficial effect of CMV hyperimmune globulin infusions in the who received a transplant from a CMV seropositive donor prophylaxis of CMV infection and disease in seronegative or who had received blood transfusions unscreened for allogeneic bone marrow transplant recipients from a CMV had no apparent benefit from treatment with CMV seropositive donor. hyperimmune globulin. There was no reduction in CMV infection, disease or seroconversion as compared with patients not given immunoglobulin.
The effects of CMV hyperimmune globulin infusions in Acknowledgements the prevention of CMV infection and disease in CMV seronegative BMT recipients have been studied in several 
